ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.69% | 71.27% | 64.12% | 72.66% | 103.24% |
| Total Depreciation and Amortization | -9.42% | -12.04% | -11.30% | -25.96% | 14.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.18% | -97.46% | -114.43% | -128.87% | -257.84% |
| Change in Net Operating Assets | -496.34% | -205.04% | -8,587.43% | -2,260.19% | 740.85% |
| Cash from Operations | -50.98% | -14.68% | -17.10% | -30.36% | -1.86% |
| Capital Expenditure | -1,266.08% | -1,691.95% | -1,793.31% | -796.75% | -1,525.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.54% | 77.03% | 64.29% | -68.74% | -76.46% |
| Cash from Investing | 32.34% | 39.31% | 20.15% | -890.78% | 18.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68.79% | 133.71% | 584.24% | 628.75% | 183.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68.79% | 133.71% | 584.24% | 628.75% | 183.08% |
| Foreign Exchange rate Adjustments | 631.71% | 171.08% | 153.85% | 127.66% | 10.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.41% | 61.74% | 298.67% | -206.64% | 72.71% |